News

Two Antiviral Drugs, Lopinavir & Ritonavir, Fail To Treat Coronavirus In Clinical Trials

Two antiviral drugs that seemed like a promising treatment for the novel coronavirus, or COVID-19, failed during clinical trials in seriously ill patients in China.

“No benefit was observed,” the researchers wrote in The New England Journal of Medicine.

The study, published Wednesday, tested Kaletra, a combination of two antiviral medicines, lopinavir and ritonavir, that are normally used to treat H.I.V.

“This randomized trial found that lopinavir–ritonavir treatment added to standard supportive care was not associated with clinical improvement or mortality in seriously ill patients with COVID-19 different from that associated with standard care alone,” the study read.

Subscribe to our free weekly newsletter!

A week of political news in your in-box.
We find the news you need to know, so you don't have to.

The drugs had been used to treat coronavirus patients in both Queensland and South Korea, though the discouraging results of the trial will point researchers towards other drugs.

One potentially promising drug is chloroquine, an anti-malarial prescription drug that has been used since the 1940s. Tesla CEO Elon Musk endorsed the idea of using it on Twitter, and a few days later President Donald Trump ordered the Food and Drug Administration to fast track research into its effectiveness against COVID-19.

There is currently a large trial of remdesivir taking place in Seattle. Since the drug is not currently approved by the FDA for treating coronavirus, hospitals must be a part of the study to receive dosages. Hospitals not involved in the study may be able to apply for “compassionate use,” special permission sometimes granted by the FDA to receive an experimental drug outside of a study.

Even with trials being fast-tracked, drug approval takes a long time. At the current rate of research, most estimate the earliest a treatment drug for COVID-19 would be available on the market is July.

“There are trials going on for some of these things in some areas,” Town said. “All are rapidly enrolling, but their data won’t be back in time for a lot of places to make these decisions.”

Katherine Huggins

Recent Posts

Democrats Attack Green Party Nominee Jill Stein In New Ad

A new ad about Green Party candidate Jill Stein has been released by Vice President Kamala Harris'…

10 hours ago

Jennifer Lopez Says Trump ‘Offended Every Latino In The Country’ With MSG Joke At Harris Rally

https://youtu.be/inbJpo6D4BQ Jennifer Lopez, campaigning with Kamala Harris on Oct. 31 in Nevada, said Donald Trump’s…

10 hours ago

Trump National Security Adviser Michael Flynn Says ‘Gates Of Hell’ Will Be Opened On Opponents If Trump Is Reelected

Former National Security Adviser Michael Flynn declared that the "gates of hell" would be unleashed if former…

2 days ago

VIDEO: Kamala Harris Hugs First Person In Line For Her Ellipse Rally, Chats With Her Mom

https://youtu.be/JQCdk-71tG0 Democratic presidential nominee Kamala Harris met with the woman who was the first in…

2 days ago

VIDEO: Harris Vows To Put ‘Country Above Party’ In Front Of 75,000 People At The Ellipse

https://youtu.be/xc72fdqkaVc Vice President Kamala Harris vowed to put “country above party and above self” as…

3 days ago

Trump-Friendly Judge Aileen Cannon In The Running For Attorney General If Former President Wins Second Term

U.S. District Judge Aileen Cannon has reportedly been placed on a list of potential attorney general candidates…

3 days ago